Cambridge Heart Inc

Cambridge Heart — Investor Presentation (June 2010)

27 slides from Cambridge Heart's investor presentation, Jun 9, 2010

  1. Slide 1: Investor Presentation June 7, 2010

    Investor Presentation June 7, 2010 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 2 Statements in this presentation that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about existing and potential partnerships and distribution a

  3. Slide 3: Corporate Mandates

    Corporate Mandates Impact the number of deaths from sudden cardiac arrest (SCA) from today’s 300,000 – 400,000 annual incidents Make MTWA testing a standard annual diagnostic assessment of ~12 million high-risk cardiac patients Leverage MTWA core technology into new, broader-based diagnostic cardiac

  4. Slide 4: The Opportunity

    The Opportunity New business model, major risks eliminated, attractive valuation Key components for success in place Recurring revenue stream builds shareholder value 4 – Large addressable market of ~ 12 million high risk cardiac patients – FDA Clearance – CMS and private reimbursement in place – Si

  5. Slide 5: Overview & Milestones

    Overview & Milestones 1980’s: Early research at MIT 1990: CHI was founded 1994: Landmark publication in NEJM 1996: Initial public offering (CAMH) 1996: First 510(k) & CH2000 launch 1999: Regulatory study completed & received FDA labeling claims 2000: HearTwave I launch 2005: HearTwave II launch 2006

  6. Slide 6: High SCA Risk Population: Large US Market Opportunity

    High SCA Risk Population: Large US Market Opportunity ~ 12 million high-risk individuals Circulation 2/10/2006 Heart Disease and Stroke Statistics 300,000 – 400,000 deaths per year 6 5 million Heart Failure 1-2 million other 8 million Post MI

  7. Slide 7: Microvolt T-Wave Alternans (MTWA)

    Microvolt T-Wave Alternans (MTWA) More effective at identifying at-risk SCA patients than invasive electrophysiology (EP) test Extraordinary negative predictive value (NPV) Ensure delivery of appropriate therapy 7 HearTwave® II

  8. Slide 8: The Technology: MTWA Analytic Spectral Method

    The Technology MTWA Analytic Spectral Method Even Beats Odd Beats Mean V alt V alt Q R S T 8 13 patents protect all components of the technology

  9. Slide 9: Clinical Validation

    Clinical Validation 200+ publications in peer-reviewed journals Large prospective clinical trials Applicable patient populations 9 – ALPHA Study - Boston Scientific – ABCD Study – St. Jude Medical – MASTER Study -- Medtronic – Ikeda Study – Meta Analysis – Hahnloser (March 2009 HRS Supplement) – Pri

  10. Slide 10: Class IIa Guideline

    Class IIa Guideline American College of Cardiology/American Heart Assoc./European Society of Cardiology 2006 Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (Developed in collaboration with the HRS and EHRA) – Class IIa It is reasonable to

  11. Slide 11: CMS National Coverage

    CMS National Coverage “CMS (Medicare) has determined that there is sufficient evidence to conclude that Microvolt T- wave Alternans (MTWA) diagnostic testing is for the evaluation of patients at risk of sudden cardiac death, only is used, and CMS is issuing the following national coverage determinat

  12. Slide 12: Medicare Reimbursement

    Medicare Reimbursement National Average: $196 – Reimbursement is limited if MTWA is performed at the same time as standard stress, stress echo or nuclear stress testing – Negatively impacts physician’s ability to integrate MTWA testing for high-risk cardiac patients CHI has requested that CMS remove

  13. Slide 13: Private Coverage

    Private Coverage Private payers followed CMS: Coverage typically for ICD indicated population Other private payers in progress 13 – Aetna, Cigna, Humana – HCSC, BC/BS of NY, Horizon (NJ), Care First, MI, IA, SD, MN, KS, Wellmark, Premera, BCBS of AZ – Harvard Pilgirim – Regionals: GHI, Tufts, Med. M

  14. Slide 14: Initial Market Positioning

    Initial Market Positioning 14 Historical clinical positioning and marketing linked MTWA testing to ICD therapy That positioning limited the market opportunity and perception of MTWA testing Additional Challenges – 300,000 to 1 million primary prevention patients – Focus on EP community and testing o

  15. Slide 15: New Strategic Direction

    New Strategic Direction Position MTWA as a tool to “ assess ” and “ manage ” an individual’s risk of SCA in the high risk population Make MTWA more accessible to the high risk population Re-organize resources on the primary corporate value driver (i.e. sensor utilization) 15 – Develop multiple produ

  16. Slide 16: SCA Risk Management in Preserved EF Population

    SCA Risk Management in Preserved EF Population Non-device interventions for reducing SCA risk Adapted from Myerburg, NEJM 2009; 360(9):938.

  17. Slide 17: New Strategic Direction: Target Population

    300,000 – 1,000,000 primary prevention population Reluctant / borderline Patients New Strategic Direction ~ 12 million post MI, HF and other high risk patients ~ 40,000,000 Cardiac stress tests per year

  18. Slide 18: OEM Alternans Module

    OEM Alternans Module Taps into existing market for stress systems Materially improves physician ROI Significantly simplifies practice integration (1) Source: Frost & Sullivan, 2009 Report. US market data only. 18 – Approximately 4,000 units sold per year (1) with an estimated installed base of 35,00

  19. Slide 19: First Partnership Signed: Cardiac Science

    First Partnership Signed Cardiac Science: US stress market leader • Module end-user pricing in-line with other stress upgrades/options ($5-$8k). • End-user sensor pricing in-line with current CHI of $64 to $84 per sensor. – Partner will sell directly to the end-user and retain a portion of the reven

  20. Slide 20: 2010 Strategic Initiatives: Other Platforms and Embodiments

    2010 Strategic Initiatives MTWA Module – Other Stress Platforms MTWA Module – Other embodiments Heartwave II System • Geography not covered by CHI’s existing direct sales force. 20 – CHI’s current development work is portable to other manufacturer’s cardiac stress platforms – Ambulatory Holter platf

  21. Slide 21: 2010 Strategic Initiatives: Ischemia Application

    2010 Strategic Initiatives Ischemia Application MTWA and Pharmacological Agents 21 – Data suggest MTWA can identify ischemia missed by current tests – Pilot study to begin in July 2010 • PI identified • Protocol completed • IRB approval in progress – Drug development phase – Resuscitation of failed

  22. Slide 22: The Market Opportunity

    The Market Opportunity Disposable sensor gross margin in excess of 70% 10% Penetration of ~12 million high risk patients: 25% Penetration of ~12 million high risk patients: 22 COGS reductions opportunity based on volume $60 Million in annual recurring revenue from the sale of proprietary sensors $15

  23. Slide 23: MTWA Module Metrics

    MTWA Module Metrics Upfront Module Revenue Recurring Sensor Revenue Possible Range of Sensor Utilization/System 23 – $1,000 - $5,000 (platform/channel dependant) – 70% - 90% gross margin – $35 - $70 per MTWA test (platform/channel dependant) – +70% gross margin – 70 to 140 sensors/system/year

  24. Slide 24: Cash Flow Summary

    Cash Flow Summary Current Quarterly Revenue - $800,000 + 20% Quarterly Cash Expenditures - $1,900,000 Quarterly Cash Burn - $1,100,000 plus CAPEX Cash at March 31, 2010 – $2.2 million 24 – U.S. HearTwave Systems – U.S. Sensor revenue – All other (includes service and ROW sales) – Largely fixed cash

  25. Slide 25: Capital Structure

    Capital Structure Series C-1 Convertible Preferred (SJM Mar 2007) Series D Convertible Preferred (Dec 2009) Capital Structure (on as converted and exercised basis) 25 – $12.5 million junior liquidation preference – Converts into 4.2 million common shares at $2.99 – Purchased by directors and existin

  26. Slide 26: The Opportunity

    The Opportunity New business model, major risks eliminated, low valuation Key components for success in place Recurring revenue stream builds shareholder value 26 – Large addressable market of ~ 12 million high risk cardiac patients – FDA Clearance – CMS and private reimbursement in place – Signific

  27. Slide 27: Investor Presentation June 7, 2010

    Investor Presentation June 7, 2010

Cambridge Heart — Investor Presentation (June 2010) on 6ix